{"id":"ibandronic-acid","rwe":[{"pmid":"41880230","year":"2026","title":"Evaluation of compliance, persistence, safety profile and satisfaction to monthly single-pill treatment regimen of ibandronic acid 150 mg and cholecalciferol 22,400 IU among postmenopausal women with osteoporosis.","finding":"","journal":"Current medical research and opinion","studyType":"Clinical Study"},{"pmid":"41815700","year":"2026","title":"Minimally Invasive Prophylactic Plating for Bisphosphonate-induced Atypical Femoral Fracture Post Total Hip Replacement.","finding":"","journal":"Journal of orthopaedic case reports","studyType":"Clinical Study"},{"pmid":"41724764","year":"2026","title":"The performance of (68)Ga-DOTA-IBA PET/CT for detecting bone metastases compared with (99m)Tc-MDP bone scintigraphy.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41678784","year":"2026","title":"Increased Uptake of 68Ga-DOTA-IBA in Polymorphous Adenocarcinoma of the Parotid Gland.","finding":"","journal":"Clinical nuclear medicine","studyType":"Clinical Study"},{"pmid":"40794284","year":"2025","title":"[Severe degenerative changes of the temporomandibular joint associated with diffuse sclerosing osteomyelitis].","finding":"","journal":"HNO","studyType":"Clinical Study"}],"tags":[{"label":"Bisphosphonate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Farnesyl pyrophosphate synthase","category":"target"},{"label":"FDPS","category":"gene"},{"label":"GGPS1","category":"gene"},{"label":"M05BA06","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Oral","category":"route"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Hypercalcemia","category":"indication"},{"label":"Postmenopausal osteoporosis","category":"indication"},{"label":"Hoffmann La Roche","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Bone Density Conservation Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":1772.59,"date":"","count":746,"signal":"Osteonecrosis of jaw","source":"DrugCentral FAERS","actionTaken":"Reported 746 times (LLR=1773)"},{"llr":1607.203,"date":"","count":688,"signal":"Femur fracture","source":"DrugCentral FAERS","actionTaken":"Reported 688 times (LLR=1607)"},{"llr":759.041,"date":"","count":381,"signal":"Osteonecrosis","source":"DrugCentral FAERS","actionTaken":"Reported 381 times (LLR=759)"},{"llr":703.837,"date":"","count":201,"signal":"Low turnover osteopathy","source":"DrugCentral FAERS","actionTaken":"Reported 201 times (LLR=704)"},{"llr":683.245,"date":"","count":446,"signal":"Bone pain","source":"DrugCentral FAERS","actionTaken":"Reported 446 times (LLR=683)"},{"llr":535.225,"date":"","count":174,"signal":"Atypical femur fracture","source":"DrugCentral FAERS","actionTaken":"Reported 174 times (LLR=535)"},{"llr":433.825,"date":"","count":167,"signal":"Stress fracture","source":"DrugCentral FAERS","actionTaken":"Reported 167 times (LLR=434)"},{"llr":358.968,"date":"","count":516,"signal":"Myalgia","source":"DrugCentral FAERS","actionTaken":"Reported 516 times (LLR=359)"},{"llr":295.388,"date":"","count":87,"signal":"Intramedullary rod insertion","source":"DrugCentral FAERS","actionTaken":"Reported 87 times (LLR=295)"},{"llr":275.922,"date":"","count":87,"signal":"Fracture nonunion","source":"DrugCentral FAERS","actionTaken":"Reported 87 times (LLR=276)"},{"llr":273.016,"date":"","count":240,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 240 times (LLR=273)"},{"llr":239.761,"date":"","count":170,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 170 times (LLR=240)"},{"llr":231.583,"date":"","count":87,"signal":"Exposed bone in jaw","source":"DrugCentral FAERS","actionTaken":"Reported 87 times (LLR=232)"},{"llr":221.275,"date":"","count":116,"signal":"Injection site extravasation","source":"DrugCentral FAERS","actionTaken":"Reported 116 times (LLR=221)"},{"llr":219.526,"date":"","count":731,"signal":"Fall","source":"DrugCentral FAERS","actionTaken":"Reported 731 times (LLR=220)"}],"commonSideEffects":[{"effect":"Arthralgia","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Back pain","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Pain in extremity","drugRate":"5%","severity":"common","organSystem":""}],"contraindications":["Achalasia of esophagus","Acute nephropathy","Acute peptic ulcer","Aseptic necrosis of bone of jaw","Bed-ridden","Bone pain","Duodenitis","Dysphagia","Esophageal dysmotility","Esophagitis","Fracture of femur","Gastritis","Heartburn","Hypocalcemia","Invasive Dental Procedure","Joint pain","Muscle pain","Primary malignant neoplasm","Stricture of esophagus","Swallowing painful","Tooth disorder","Ulcer of esophagus","Vitamin D deficiency"],"specialPopulations":{"Lactation":"BONIVA is not indicated for use in women of reproductive potential. There is no information on the presence of ibandronate in human milk, the effects of ibandronate on the breastfed infant, or the effects of ibandronate on milk production. Ibandronate is present in rat milk (see Data). The clinical relevance of these data is unclear.","Pregnancy":"Ibandronate sodium is not indicated for use in women of reproductive potential. There are no data with ibandronate sodium use in pregnant women to inform any drug-associated risks. In reproductive toxicity studies in the rat, ibandronate sodium caused obstruction of labor, with maternal periparturient mortality, pup loss and reduced pup weight at greater than or equal to times human exposure at the recommended human intravenous dose of mg. Abnormal pup odontogeny was observed at greater than or equal to 18 times human exposure.","Geriatric use":"Of the patients receiving ibandronate sodium injection mg every months for year, 51% were over 65 years of age. No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity in some older individuals cannot be ruled out.","Paediatric use":"Safety and effectiveness of ibandronate sodium injection in pediatric patients have not been established."},"seriousAdverseEvents":[{"effect":"Serious adverse events","drugRate":"23%","severity":"serious"},{"effect":"All-cause mortality","drugRate":"1.2%","severity":"serious"},{"effect":"Ocular inflammation (iritis, scleritis)","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Hoffmann La Roche","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2023-05-06","territory":"US","patentNumber":"7192938"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-05-06","territory":"US","patentNumber":"7410957"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-05-06","territory":"US","patentNumber":"7718634"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IBANDRONIC ACID","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:40:15.167664+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:40:15.166094+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:40:49.092943+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:40:21.745951+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:40:15.187757+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IBANDRONIC ACID","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:40:22.515822+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL997/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:40:23.914127+00:00"}},"allNames":"boniva","offLabel":[],"synonyms":["bonviva","ibandronic acid","ibandronate","boniva","ibandronate sodium"],"timeline":[{"date":"1996-06-25","type":"positive","source":"DrugCentral","milestone":"EMA approval (Atnahs Pharma Netherlands B.V.)"},{"date":"2003-05-16","type":"positive","source":"DrugCentral","milestone":"FDA approval (Hoffmann La Roche)"}],"aiSummary":"Ibandronic Acid (Boniva), marketed by Hoffmann La Roche, is a bisphosphonate primarily indicated for hypercalcemia, competing in a well-established class of drugs with key competitors such as etidronic acid, pamidronic acid, alendronic acid, tiludronic acid, and risedronic acid. Boniva's mechanism of action, which involves binding to hydroxyapatite in bone to inhibit osteoclast-mediated bone resorption, provides a strong therapeutic foundation and differentiates it within the bisphosphonate class. The primary risk to Boniva's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.","brandName":"Boniva","ecosystem":[{"indication":"Hypercalcemia","otherDrugs":[{"name":"edetic acid","slug":"edetic-acid","company":"Medicis"}],"globalPrevalence":null},{"indication":"Postmenopausal osteoporosis","otherDrugs":[{"name":"alendronic acid","slug":"alendronic-acid","company":"Merck And Co Inc"},{"name":"bazedoxifene","slug":"bazedoxifene","company":"Wyeth Pharms Pfizer"},{"name":"calcitonin (salmon synthetic)","slug":"calcitonin-(salmon-synthetic)","company":"Sanofi Aventis Us"},{"name":"calcium citrate","slug":"calcium-citrate","company":""}],"globalPrevalence":200000000}],"mechanism":{"target":"Farnesyl pyrophosphate synthase","novelty":"Follow-on","targets":[{"gene":"FDPS","source":"DrugCentral","target":"Farnesyl pyrophosphate synthase","protein":"Farnesyl pyrophosphate synthase"},{"gene":"GGPS1","source":"DrugCentral","target":"Geranylgeranyl pyrophosphate synthase","protein":"Geranylgeranyl pyrophosphate synthase"}],"modality":"Small Molecule","drugClass":"Bisphosphonate","explanation":"","oneSentence":"","technicalDetail":"Boniva (Ibandronate) acts as a bisphosphonate by binding to hydroxyapatite in bone, inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway, which is essential for osteoclast function and bone resorption."},"commercial":{"launchDate":"2003","_launchSource":"DrugCentral (FDA 2003-05-16, HOFFMANN LA ROCHE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1404","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IBANDRONIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IBANDRONIC ACID","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:42:26.022803","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:40:49.093623+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"etidronic acid","drugSlug":"etidronic-acid","fdaApproval":"1977-09-01","relationship":"same-class"},{"drugName":"pamidronic acid","drugSlug":"pamidronic-acid","fdaApproval":"1991-10-31","relationship":"same-class"},{"drugName":"alendronic acid","drugSlug":"alendronic-acid","fdaApproval":"1995-09-29","relationship":"same-class"},{"drugName":"tiludronic acid","drugSlug":"tiludronic-acid","fdaApproval":"1997-03-07","relationship":"same-class"},{"drugName":"risedronic acid","drugSlug":"risedronic-acid","fdaApproval":"1998-03-27","relationship":"same-class"},{"drugName":"zoledronic acid","drugSlug":"zoledronic-acid","fdaApproval":"2001-08-20","patentExpiry":"Feb 5, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"ibandronic acid","indications":{"approved":[{"name":"Hypercalcemia","source":"DrugCentral","snomedId":66931009,"regulator":"FDA","eligibility":{"age":"no age restriction","other":"no additional eligibility criteria specified","stage":"hypercalcemia","prior treatment":"none specified"}},{"name":"Postmenopausal osteoporosis","source":"DrugCentral","snomedId":102447009,"regulator":"FDA","usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"etidronic-acid","brandName":"etidronic acid","genericName":"etidronic acid","approvalYear":"1977","relationship":"same-class"},{"drugId":"pamidronic-acid","brandName":"pamidronic acid","genericName":"pamidronic acid","approvalYear":"1991","relationship":"same-class"},{"drugId":"alendronic-acid","brandName":"alendronic acid","genericName":"alendronic acid","approvalYear":"1995","relationship":"same-class"},{"drugId":"tiludronic-acid","brandName":"tiludronic acid","genericName":"tiludronic acid","approvalYear":"1997","relationship":"same-class"},{"drugId":"risedronic-acid","brandName":"risedronic acid","genericName":"risedronic acid","approvalYear":"1998","relationship":"same-class"},{"drugId":"zoledronic-acid","brandName":"zoledronic acid","genericName":"zoledronic acid","approvalYear":"2001","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07406685","phase":"PHASE4","title":"The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-03-17","conditions":["Postmenopausal Osteoporosis","Postmenopausal Osteopenia","Primary Osteoporosis","Osteoporosis"],"enrollment":52,"completionDate":"2030-09-17"},{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":["Osteoporosis","Osteoporosis, Postmenopausal"],"enrollment":40,"completionDate":"2026-04-15"},{"nctId":"NCT07043608","phase":"PHASE2","title":"Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases","status":"NOT_YET_RECRUITING","sponsor":"Kelly Fitzgerald, MD","startDate":"2025-09-30","conditions":["Clear Cell Renal Cell Cancer (ccRCC)","Clear Cell Renal Carcinoma","Clear Cell Renal Cell Carcinoma Metastatic","Clear Cell Renal Cancer","Bone Metastases of a Malignant Tumor","Clear Cell Renal Cell Carcinoma","Bone, Metastatic Cancer","Metastatic Cancer","Metastatic Renal Cell Carcinoma","Metastases to Bone"],"enrollment":20,"completionDate":"2029-09-30"},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":["Osteoporosis"],"enrollment":517991,"completionDate":"2023-07-21"},{"nctId":"NCT04321837","phase":"PHASE2","title":"Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-02-05","conditions":["Osteoporosis, Postmenopausal"],"enrollment":60,"completionDate":"2023-03-13"},{"nctId":"NCT02635997","phase":"","title":"Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America","status":"COMPLETED","sponsor":"Pontifical Catholic University of Argentina","startDate":"2013-01","conditions":["Osteoporosis"],"enrollment":425,"completionDate":"2015-06"},{"nctId":"NCT06022237","phase":"NA","title":"Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-09-01","conditions":["Hepatic Osteodystrophy","Liver Cirrhosis"],"enrollment":80,"completionDate":"2024-08-30"},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":["Osteoporosis","Osteoporosis Fracture","Drug Therapy","Mortality","Adherence, Medication"],"enrollment":216155,"completionDate":"2021-10-31"},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":["Osteoporosis, With or Without Treatment","Bisphosphonate Treatment","Atypical Femur Fracture","Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ)","Healthy Volunteers"],"enrollment":314,"completionDate":"2022-10-30"},{"nctId":"NCT05266261","phase":"NA","title":"Use of Ibandronate in Diabetic Patients","status":"COMPLETED","sponsor":"Yeouido St. Mary's Hospital","startDate":"2018-10-01","conditions":["Osteoporosis, Postmenopausal","Type 2 Diabetes"],"enrollment":121,"completionDate":"2022-01-31"},{"nctId":"NCT01077817","phase":"","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-02-26","conditions":["Esophageal Cancer","Squamous Cell Carcinoma","Adenocarcinoma"],"enrollment":684815,"completionDate":"2012-02-16"},{"nctId":"NCT00092053","phase":"PHASE3","title":"Study of Investigational Drug in Osteoporosis (MK-0217-908)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12","conditions":["Postmenopausal Osteoporosis"],"enrollment":203,"completionDate":"2005-07"},{"nctId":"NCT03186131","phase":"PHASE2","title":"Efficacy of Oral Ibandronate in Osteoporosis","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2017-10-12","conditions":["Osteoporosis"],"enrollment":100,"completionDate":"2025-06-08"},{"nctId":"NCT02156999","phase":"PHASE4","title":"Changes of Bone Turnover Markers and Bone Mineral Density After Osteoporosis Treatment","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2014-06","conditions":["Osteoporosis"],"enrollment":100,"completionDate":"2025-12"},{"nctId":"NCT00127205","phase":"PHASE3","title":"S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2005-07","conditions":["Breast Cancer"],"enrollment":6097,"completionDate":"2021-03-29"},{"nctId":"NCT02616744","phase":"PHASE2","title":"Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2011-01","conditions":["Breast Cancer"],"enrollment":171,"completionDate":"2016-05"},{"nctId":"NCT00662077","phase":"PHASE4","title":"Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort","status":"WITHDRAWN","sponsor":"Germans Trias i Pujol Hospital","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT01406613","phase":"","title":"Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2010-03","conditions":["Postmenopausal Osteoporosis"],"enrollment":86,"completionDate":"2015-11"},{"nctId":"NCT02731040","phase":"","title":"Exome Sequencing for Atypical Femoral Fractures","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04","conditions":["Atypical Femoral Fractures","Osteoporosis","Bisphosphonate Therapy"],"enrollment":38,"completionDate":"2018-03-29"},{"nctId":"NCT00824993","phase":"PHASE3","title":"Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-12-09","conditions":["Hematological Malignancies"],"enrollment":78,"completionDate":"2017-04-07"},{"nctId":"NCT00405392","phase":"PHASE4","title":"Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-22","conditions":["Osteoporosis, Postmenopausal"],"enrollment":365,"completionDate":"2008-05-27"},{"nctId":"NCT00048061","phase":"PHASE3","title":"MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-04","conditions":["Post Menopausal Osteoporosis"],"enrollment":1609,"completionDate":"2004-12"},{"nctId":"NCT00666627","phase":"PHASE2","title":"Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-04","conditions":["Post-menopausal Osteoporosis"],"enrollment":410,"completionDate":"2014-12"},{"nctId":"NCT00099203","phase":"PHASE3","title":"A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":["Pain","Bone Neoplasm","Neoplasm Metastasis"],"enrollment":163,"completionDate":"2007-12"},{"nctId":"NCT00478270","phase":"PHASE2","title":"A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":["Pain","Bone Neoplasm","Neoplasm Metastasis"],"enrollment":0,"completionDate":"2008-02"},{"nctId":"NCT00099177","phase":"PHASE3","title":"A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2005-08","conditions":["Pain","Bone Neoplasm","Neoplasm Metastasis"],"enrollment":96,"completionDate":"2007-12"},{"nctId":"NCT00081653","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-05","conditions":["Post-Menopausal Osteoporosis"],"enrollment":719,"completionDate":"2008-05"},{"nctId":"NCT00327990","phase":"PHASE4","title":"Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":["Osteoporosis"],"enrollment":300,"completionDate":"2006-12"},{"nctId":"NCT02114489","phase":"PHASE3","title":"Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis","status":"TERMINATED","sponsor":"Brigitte Jolles, MD","startDate":"2014-06","conditions":["Aseptic Hip Necrosis","Hip Necrosis"],"enrollment":8,"completionDate":"2017-03"},{"nctId":"NCT00545207","phase":"PHASE3","title":"A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":["Post-Menopausal Osteopenia"],"enrollment":150,"completionDate":"2010-09"},{"nctId":"NCT00545090","phase":"PHASE4","title":"ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-08","conditions":["Post Menopausal Osteoporosis"],"enrollment":561,"completionDate":"2008-06"},{"nctId":"NCT00148915","phase":"PHASE4","title":"A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-08","conditions":["Osteoporosis"],"enrollment":98,"completionDate":"2007-08"},{"nctId":"NCT02564107","phase":"PHASE4","title":"A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":["Pain; Bone Neoplasms; Neoplasm Metastasis"],"enrollment":48,"completionDate":"2006-04"},{"nctId":"NCT02598453","phase":"PHASE4","title":"PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-01","conditions":["Postmenopausal Osteoporosis"],"enrollment":545,"completionDate":"2006-09"},{"nctId":"NCT02604836","phase":"PHASE4","title":"A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":["Postmenopausal Osteoporosis"],"enrollment":1711,"completionDate":"2006-04"},{"nctId":"NCT02598440","phase":"PHASE4","title":"A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":["Postmenopausal Osteoporosis"],"enrollment":341,"completionDate":"2005-05"},{"nctId":"NCT01128257","phase":"","title":"A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-04","conditions":["Postmenopausal Osteoporosis"],"enrollment":6054,"completionDate":"2011-12"},{"nctId":"NCT00493532","phase":"","title":"A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.","status":"NO_LONGER_AVAILABLE","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":["Postmenopausal Osteoporosis"],"enrollment":0,"completionDate":"2010-12"},{"nctId":"NCT02561039","phase":"PHASE3","title":"A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":["Pain; Bone Neoplasms; Neoplasm Metastasis"],"enrollment":97,"completionDate":"2008-03"},{"nctId":"NCT00545909","phase":"PHASE4","title":"BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-03","conditions":["Postmenopausal Osteoporosis"],"enrollment":585,"completionDate":"2008-08"},{"nctId":"NCT02553850","phase":"","title":"An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":["Breast Cancer"],"enrollment":442,"completionDate":"2010-01"},{"nctId":"NCT01429675","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-08","conditions":["Healthy"],"enrollment":105,"completionDate":"2012-03"},{"nctId":"NCT01581320","phase":"PHASE3","title":"Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-12","conditions":["Postmenopausal Women With Osteoporosis"],"enrollment":201,"completionDate":"2012-09"},{"nctId":"NCT01577849","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2012-03","conditions":["Healthy"],"enrollment":36,"completionDate":"2012-06"},{"nctId":"NCT02948881","phase":"PHASE4","title":"A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-08","conditions":["Osteoporosis"],"enrollment":100,"completionDate":"2007-07"},{"nctId":"NCT00545779","phase":"PHASE3","title":"BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":["Post-Menopausal Osteoporosis"],"enrollment":677,"completionDate":"2008-10"},{"nctId":"NCT00545363","phase":"PHASE4","title":"A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-04","conditions":["Postmenopausal Osteoporosis"],"enrollment":716,"completionDate":"2008-01"},{"nctId":"NCT00377234","phase":"PHASE4","title":"A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":["Post Menopausal Osteoporosis"],"enrollment":356,"completionDate":"2008-08"},{"nctId":"NCT02739594","phase":"PHASE3","title":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-02","conditions":["Multiple Myeloma"],"enrollment":89,"completionDate":"2009-04"},{"nctId":"NCT00545051","phase":"PHASE4","title":"A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":["Postmenopausal Osteoporosis"],"enrollment":140,"completionDate":"2009-05"},{"nctId":"NCT00303485","phase":"PHASE4","title":"A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-02","conditions":["Post Menopausal Osteoporosis"],"enrollment":67,"completionDate":"2007-06"},{"nctId":"NCT02716792","phase":"PHASE3","title":"A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-01","conditions":["Pain; Bone Neoplasms; Neoplasm Metastasis"],"enrollment":334,"completionDate":"2008-08"},{"nctId":"NCT02598934","phase":"PHASE4","title":"A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-08","conditions":["Post Menopausal Osteoporosis"],"enrollment":308,"completionDate":"2006-05"},{"nctId":"NCT00493623","phase":"PHASE3","title":"BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":["Osteoporosis"],"enrollment":68,"completionDate":"2009-12"},{"nctId":"NCT00492843","phase":"PHASE4","title":"Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis","status":"TERMINATED","sponsor":"Chinese Society of Lung Cancer","startDate":"2007-07","conditions":["Lung Cancer"],"enrollment":20,"completionDate":"2008-07"},{"nctId":"NCT00048074","phase":"PHASE3","title":"DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-06","conditions":["Post Menopausal Osteoporosis"],"enrollment":1395,"completionDate":"2005-05"},{"nctId":"NCT00129623","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-12","conditions":["Post-Menopausal Osteopenia"],"enrollment":160,"completionDate":"2007-12"},{"nctId":"NCT02553707","phase":"PHASE4","title":"A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07","conditions":["Pain; Bone Neoplasms; Neoplasm Metastasis"],"enrollment":182,"completionDate":"2008-12"},{"nctId":"NCT00532220","phase":"PHASE3","title":"Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2007-12","conditions":["Osteonecrosis of the Knee","Bone Marrow Edema of the Knee"],"enrollment":30,"completionDate":"2015-08"},{"nctId":"NCT02528747","phase":"","title":"A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-01","conditions":["Metastatic Breast Cancer"],"enrollment":582,"completionDate":"2011-12"},{"nctId":"NCT00545480","phase":"PHASE4","title":"SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07","conditions":["Post Menopausal Osteoporosis"],"enrollment":596,"completionDate":"2009-03"},{"nctId":"NCT01290094","phase":"PHASE3","title":"A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04","conditions":["Post Menopausal Osteoporosis"],"enrollment":41,"completionDate":"2014-07"},{"nctId":"NCT01287533","phase":"PHASE4","title":"Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids","status":"COMPLETED","sponsor":"Yeong-Wook Song","startDate":"2010-04","conditions":["Rheumatoid Arthritis","Osteoporosis","Osteopenia"],"enrollment":167,"completionDate":"2014-04"},{"nctId":"NCT00446589","phase":"PHASE4","title":"The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density","status":"TERMINATED","sponsor":"Papageorgiou General Hospital","startDate":"2006-07","conditions":["Osteoporosis"],"enrollment":19,"completionDate":""},{"nctId":"NCT02271204","phase":"","title":"Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Clinic of Endocrinology and Metabolic Disorders, Macedonia","startDate":"2009-03","conditions":["Osteoporosis"],"enrollment":700,"completionDate":"2014-04"},{"nctId":"NCT02249741","phase":"PHASE4","title":"Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation","status":"COMPLETED","sponsor":"Dr. Ashish Kumar","startDate":"2012-08","conditions":["Cirrhosis"],"enrollment":47,"completionDate":"2014-02"},{"nctId":"NCT00196859","phase":"PHASE3","title":"Study in Elderly Patients With Early Breast Cancer (ICE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2004-06","conditions":["Breast Cancer"],"enrollment":1500,"completionDate":"2014-01"},{"nctId":"NCT00196872","phase":"PHASE3","title":"A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2004-07","conditions":["Breast Cancer"],"enrollment":3000,"completionDate":"2014-06"},{"nctId":"NCT01376102","phase":"","title":"BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11","conditions":["Osteoporosis"],"enrollment":657,"completionDate":"2013-02"},{"nctId":"NCT00091832","phase":"PHASE2","title":"Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-09","conditions":["Breast Cancer","Metastases","Bone Metastases in Subjects With Advanced Breast Cancer"],"enrollment":255,"completionDate":"2006-10"},{"nctId":"NCT00502736","phase":"PHASE2","title":"A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":["Pain; Bone Neoplasms; Neoplasm Metastasis"],"enrollment":13,"completionDate":"2009-03"},{"nctId":"NCT00767169","phase":"PHASE2","title":"Bisphosphonate-coated Dental Implants","status":"COMPLETED","sponsor":"University Hospital, Linkoeping","startDate":"2008-10","conditions":["Edentatio (Toothlessness)"],"enrollment":16,"completionDate":"2011-06"},{"nctId":"NCT00301886","phase":"PHASE3","title":"S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2006-05","conditions":["Breast Cancer","Hypercalcemia of Malignancy","Metastatic Cancer","Pain"],"enrollment":0,"completionDate":"2006-05"},{"nctId":"NCT00683163","phase":"PHASE2,PHASE3","title":"PTH & Ibandronate Combination Study (PICS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-05","conditions":["Osteoporosis"],"enrollment":44,"completionDate":"2011-04"},{"nctId":"NCT00082927","phase":"PHASE3","title":"Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain","status":"COMPLETED","sponsor":"Cancer Research UK","startDate":"2003-04","conditions":["Metastatic Cancer","Pain","Prostate Cancer"],"enrollment":580,"completionDate":"2011-07"},{"nctId":"NCT00873808","phase":"","title":"S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-10","conditions":["Breast Cancer"],"enrollment":0,"completionDate":"2010-02"},{"nctId":"NCT00326820","phase":"PHASE3","title":"Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer","status":"UNKNOWN","sponsor":"Wales Cancer Trials Unit","startDate":"2006-01","conditions":["Breast Cancer","Hypercalcemia of Malignancy","Metastatic Cancer"],"enrollment":1404,"completionDate":"2015-10"},{"nctId":"NCT00936897","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-07","conditions":["Postmenopausal Osteoporosis"],"enrollment":833,"completionDate":"2012-01"},{"nctId":"NCT01381393","phase":"","title":"BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":["Osteoporosis"],"enrollment":659,"completionDate":"2012-03"},{"nctId":"NCT00447915","phase":"PHASE3","title":"Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-03","conditions":["Primary Osteoporosis"],"enrollment":1265,"completionDate":"2011-12"},{"nctId":"NCT01627886","phase":"PHASE1","title":"Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2008-09","conditions":["Healthy"],"enrollment":100,"completionDate":"2008-10"},{"nctId":"NCT00668330","phase":"PHASE4","title":"Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2007-04","conditions":["Systemic Lupus Erythematosus"],"enrollment":40,"completionDate":"2009-05"},{"nctId":"NCT00551174","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":["Post-Menopausal Osteoporosis"],"enrollment":781,"completionDate":"2008-11"},{"nctId":"NCT00503113","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-07","conditions":["Post-Menopausal Osteoporosis"],"enrollment":801,"completionDate":"2010-04"},{"nctId":"NCT00423384","phase":"PHASE2,PHASE3","title":"Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.","status":"UNKNOWN","sponsor":"Smerud Medical Research International AS","startDate":"2007-01","conditions":["Renal Transplant"],"enrollment":130,"completionDate":"2010-12"},{"nctId":"NCT00397839","phase":"PHASE3","title":"The Effect Of Oral Ibandronate In Male Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-01","conditions":["Male Osteoporosis"],"enrollment":135,"completionDate":"2008-10"},{"nctId":"NCT00271713","phase":"PHASE4","title":"Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2006-03","conditions":["Osteoporosis, Postmenopausal"],"enrollment":70,"completionDate":"2007-09"},{"nctId":"NCT00381368","phase":"PHASE2","title":"Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients","status":"UNKNOWN","sponsor":"University of Turku","startDate":"2006-10","conditions":["Breast Cancer"],"enrollment":60,"completionDate":""}],"_emaApprovals":[{"date":"1996-06-25","status":"Authorised","company":"Atnahs Pharma Netherlands B.V."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous, Oral","formulation":"Injection, Tablet","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Ibandronate Sodium"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"IBANDRONATE SODIUM"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Ibandronate Sodium"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"ibandronate sodium"},{"form":"TABLET","route":"ORAL","productName":"IBANDRONATE SODIUM"},{"form":"TABLET","route":"ORAL","productName":"Ibandronate sodium"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"IBANDRONATE SODIUM"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Ibandronate Sodium"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Boniva"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"188271","NDDF":"007178","UNII":"UMD7G2653W","VANDF":"4021407","INN_ID":"7189","RXNORM":"115264","UMLSCUI":"C0379200","chemblId":"CHEMBL997","ChEMBL_ID":"CHEMBL997","KEGG_DRUG":"D08056","DRUGBANK_ID":"DB00710","PDB_CHEM_ID":" BFQ","PUBCHEM_CID":"60852","SNOMEDCT_US":"395271007","IUPHAR_LIGAND_ID":"3059","SECONDARY_CAS_RN":"138926-19-9","MESH_DESCRIPTOR_UI":"D000077557"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2003-","companyName":"Hoffmann La Roche","relationship":"Original Developer"},{"period":"1996","companyName":"Atnahs Pharma Netherlands B.V.","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"14.0 hours","clearance":"1.8 mL/min/kg","bioavailability":"1%","fractionUnbound":"0.15%","volumeOfDistribution":"0.55 L/kg"},"publicationCount":97,"therapeuticAreas":["Bone"],"atcClassification":{"source":"DrugCentral","atcCode":"M05BA06","allCodes":["M05BA06","M05BB09"]},"biosimilarFilings":[],"originalDeveloper":"Hoffmann La Roche","recentPublications":[{"date":"2026 Mar 25","pmid":"41880230","title":"Evaluation of compliance, persistence, safety profile and satisfaction to monthly single-pill treatment regimen of ibandronic acid 150 mg and cholecalciferol 22,400 IU among postmenopausal women with osteoporosis.","journal":"Current medical research and opinion"},{"date":"2026 Mar","pmid":"41815700","title":"Minimally Invasive Prophylactic Plating for Bisphosphonate-induced Atypical Femoral Fracture Post Total Hip Replacement.","journal":"Journal of orthopaedic case reports"},{"date":"2026 Feb 22","pmid":"41724764","title":"The performance of (68)Ga-DOTA-IBA PET/CT for detecting bone metastases compared with (99m)Tc-MDP bone scintigraphy.","journal":"Scientific reports"},{"date":"2026 Feb 4","pmid":"41678784","title":"Increased Uptake of 68Ga-DOTA-IBA in Polymorphous Adenocarcinoma of the Parotid Gland.","journal":"Clinical nuclear medicine"},{"date":"2025 Nov","pmid":"40794284","title":"[Severe degenerative changes of the temporomandibular joint associated with diffuse sclerosing osteomyelitis].","journal":"HNO"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Hoffmann La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"2003","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"7718634","territory":"US","patent_type":null,"expiry_date":"2023-05-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7410957","territory":"US","patent_type":null,"expiry_date":"2023-05-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7192938","territory":"US","patent_type":null,"expiry_date":"2023-05-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:40:49.093623+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}